Core therapeutic areas

Size: px
Start display at page:

Download "Core therapeutic areas"

Transcription

1 Core therapeutic areas Platforms for growth Luke Miels, Executive Vice President, Global Portfolio & Product Strategy and Corporate Affairs

2 Current business is led by core therapeutic areas Sales 9M % Infection, Neuroscience, Gastrointestinal 12% 19% 38% Oncology RIA CVMD 69% Note: RIA: Respiratory, Inflammation & Autoimmunity CVMD: Cardiovascular & Metabolic Disease 2 Core therapeutic areas

3 Broad geographical presence; Emerging Markets strength US 39% of sales Europe 25% of sales China 9% of sales Japan 9% of sales Emerging Markets (ex-china) 13% of sales ROW Established (ex-japan) 5% of sales Note: Sales 9M Core therapeutic areas

4 Respiratory, Inflammation & Autoimmunity (RIA) Cardiovascular & Metabolic Disease (CVMD) Oncology 4 Core therapeutic areas

5 Respiratory: Unique position in bringing leading medicines to patients Large & small molecules with compelling science Diversity in formulation to enable unique combinations Leading devices & choice for patients 5 Core therapeutic areas

6 Respiratory: Unmet need remains in asthma and COPD Asthma COPD Active patients, millions, 2014 GOLD-defined patients, millions, 2014 GINA step GOLD stage 1.8m severe, m severe, 60 inadequately inadequately 1-3 controlled despite 1-2 controlled despite compliance compliance Asthma prevalence Diagnosed Treated Poor control COPD prevalence Diagnosed Treated Poor control Note: G7 markets = US, France, Germany, Italy, Spain, UK, Japan Source: Decision Resources; Adelphi DSP 2012; other 6 Core therapeutic areas

7 COPD: Affects ~300 million* people; highest prevalence in developing countries Male smoking prevalence trends by region (2011) Lifetime male smoking prevalence: 60% and above % % % % Below 20% No Data * Global estimate of diagnosed and undiagnosed patients Source: Decision Resources; Adelphi DSP 2012; AZ internal analysis of G8 and ROW uplift 7 Core therapeutic areas

8 Symbicort & Pulmicort: Growth by EM / Japan, new indications & new devices Emerging Markets / Japan Market growth driven by: Improving diagnosis Improving access to drug treatment Environmental factors and smoking New indications COPD label updates COPD exacerbations US Asthma SMART labelling Mild asthma: Ex-US as needed Symbicort / PT001 open triple New devices Intelligent device EU Symbicort pmdi EU Symbicort BAI Symbicort Pearl co-suspension Pulmicort nebuliser expansion and Pearl co-formulation Source: UN Population Database, IMS Midas, other forecasts 8 Core therapeutic areas

9 Symbicort: Resilience driven by devices Negative impact of switch is well documented * Successful treatment Partially successful treatment Unsuccessful treatment Change in SABA dose Device has a very strong impact on prescription decision **,*** 57-69% of healthcare providers rate device as having very significant impact Proportion of patients (%) Switch (n=824) Non-switch (n=824) Mean 95% CI change in SABA daily dose 0% 0% 2% 4% 6% 9% 23% 32% 13% 11% Healthcare providers switch device typically in <10% of consultations Thomas M, Price D, Chrystyn H, et al. Inhaled corticosteroids for asthma: Impact of practice level device switching on asthma control. BMC Pulm Med 2009; 9: 1. ** Qual MR ; 70 HCP and 149 Patient Depth Interviews; Chn, Jpn, Ge, Sp & USA; Q Fast Forward Research *** Quant MR; 882 Physician On-line survey; Chn Jpn, Ge, Sp & USA; Q IPSOS 9 Core therapeutic areas

10 Inflammation & Autoimmunity: Strategy Progressing pipeline of first-in-class, best-in-class medicines Rheumatology Dermatology Gastrointestinal Gout Lupus Rheumatoid arthritis Co-development with Amgen Psoriasis and psoriatic arthritis Co-development with Amgen Crohn s disease Ulcerative colitis 10 Core therapeutic areas

11 Inflammation & Autoimmunity: Significant growth potential Global markets for rheumatoid arthritis, psoriasis, psoriatic arthritis, lupus, ulcerative colitis, Crohn s disease and gout $bn $50bn $30bn Now RA PsO&PsA Lupus UC&CD Gout Future Source: IMS, biologic and novel oral brand sales by indication; Decision Resources 11 Core therapeutic areas

12 Respiratory, Inflammation & Autoimmunity (RIA) Cardiovascular & Metabolic Disease (CVMD) Oncology 12 Core therapeutic areas

13 Diabetes: Significant T2D disease burden exists globally 380 million people with diabetes worldwide Anticipated to grow to 590 million by % increase in prevalence Lower T2D mortality Significant increase in Emerging Markets Source: International Diabetes Foundation Atlas 6 edition, International Diabetes federation Core therapeutic areas

14 Diabetes: Non-insulin diabetes market to continue endemic growth Expected revenues for insulin and other diabetes products $bn Other SGLT-2 GLP-1 DPP-4 Insulin Source: Decision Resources (2014), Type 2 Diabetes Therapy 14 Core therapeutic areas

15 Diabetes: Innovative portfolio spanning all non-insulin classes DPP-4 Orals SGLT-2 FDC SGLT-2 / DPP-4 saxa-dapa Injectables GLP-1 Amylin analogue 15 Core therapeutic areas

16 Brilinta: Strengthening momentum Ticagrelor also increases adenosine, augments vasodilation, coronary flow, inhibition of platelet function, and dyspnoea ATLANTIC Ambulance as effective as Cath-Lab Europe label change ESC, ATLANTIC & APOLLO PEGASUS headline Q Q DOJ closure New AHA guidelines AHA APOLLO: ~1 in 5 patients will suffer an MI, stroke or CV death within the first year after an MI Ticagrelor >clopidogrel for ischaemic guided and early invasive NSTE-ACS patients 16 Core therapeutic areas

17 Respiratory, Inflammation & Autoimmunity (RIA) Cardiovascular & Metabolic Disease (CVMD) Oncology 17 Core therapeutic areas

18 Oncology: Cancer incidence a global healthcare challenge Breast cancer treated patients Over 8.2m adults die each year from cancer Over 13m people are predicted to die from cancer in , , , , US EU5 JP CN 1,200,000 1,000, , , , ,000 0 NSCLC 1L treated patients US EU5 JP CN 100,000 80,000 60,000 40,000 20,000 Ovarian cancer 1L treated patients US EU5 JP CN Source: NSCLC: Kantar Health Patient Metrics (US, UK, Spain, Italy), AZ internal sources (France, Germany, Japan and China) Breast: Kantar Health Patient Metrics (US, EU5, Japan), AZ internal sources (China) Ovarian: Kantar Health Patient Metrics (US, EU5, Japan); Decision Resources (China, Urban) Global Incidence and Mortality Numbers: Globocan 2012 (IARC) Projection. Population forecasts taken from UN, World Populations Prospects (2012 revision) Forecast market size Decision Resources Pharmaview 18 Core therapeutic areas

19 Increasing importance of specialty care Primary care vs specialty care sales over time Future Now Primary Care Specialty Care 19 Core therapeutic areas

20 Confidence in strategy Core therapeutic areas platform for growth Broad geographical presence with strong EMs Aligned with pipeline Pipeline driving a balance of primary and specialty care 20 Core therapeutic areas

21 Core therapeutic areas Platforms for growth Luke Miels, Executive Vice President, Global Portfolio & Product Strategy and Corporate Affairs

Investor science conference call: American College of Cardiology 2015

Investor science conference call: American College of Cardiology 2015 Investor science conference call: American College of Cardiology 2015 San Diego, California, USA 16 March 2015 Cautionary statement regarding forward-looking statements In order, among other things, to

More information

+ REACTIONS. Kantar Health discusses. disease (IBD) market. pharma.

+ REACTIONS. Kantar Health discusses. disease (IBD) market. pharma. REACTIONS the evolving inflammatory bowel disease (IBD) market Kantar Health discusses the increased prevalence of ibd, how it will affect the current and future market, and opportunities for pharma. april

More information

Most countries will experience an increase in pharmaceutical spending per capita by 2018

Most countries will experience an increase in pharmaceutical spending per capita by 2018 6 Most countries will experience an increase in pharmaceutical spending per capita by 218 Pharmaceutical spending per capita, 213 versus 218 1,6 1,4 Pharmaceutical Spend per Capita 1,2 1, 8 6 4 2 US Japan

More information

Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Brochure More information from http://www.researchandmarkets.com/reports/3128342/ Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Description: Methotrexate (Rheumatoid Arthritis)

More information

AstraZeneca. Pascal Soriot, Executive Director, Chief Executive Officer 34th J.P. Morgan Healthcare Conference, San Francisco

AstraZeneca. Pascal Soriot, Executive Director, Chief Executive Officer 34th J.P. Morgan Healthcare Conference, San Francisco AstraZeneca Pascal Soriot, Executive Director, Chief Executive Officer 34th J.P. Morgan Healthcare Conference, San Francisco 12 January 2016 Forward-looking statements In order, among other things, to

More information

Diabetes Trends in the U.S.: Results from the National Health and Wellness Survey. White Paper. by Kathy Annunziata and Nikoletta Sternbach

Diabetes Trends in the U.S.: Results from the National Health and Wellness Survey. White Paper. by Kathy Annunziata and Nikoletta Sternbach White Paper Catalysts driving successful decisions in life sciences. Diabetes Trends in the U.S.: Results from the National Health and Wellness Survey by Kathy Annunziata and Nikoletta Sternbach January

More information

REFERENCE CODE GDHC225DFR PUBLICAT ION DAT E JULY 2013 FORXIGA (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC225DFR PUBLICAT ION DAT E JULY 2013 FORXIGA (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC225DFR PUBLICAT ION DAT E JULY 2013 FORXIGA (TYPE 2 DIABETES) - Executive Summary Below table provides a summary of Forxiga for Type 2 diabetes in the 10 major pharmaceutical markets

More information

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013 Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.

More information

REFERENCE CODE GDHC020POA PUBLICAT ION DATE APRIL 2014

REFERENCE CODE GDHC020POA PUBLICAT ION DATE APRIL 2014 REFERENCE CODE GDHC020POA PUBLICAT ION DATE APRIL 2014 GOUT Executive Summary Gout: Key Metrics in the Six Major Pharmaceutical Markets, 2013 2018 2013 Epidemiology Gout, diagnosed prevalent population

More information

REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC503DFR PUBLICAT ION DATE DECEMBER 2014 METHOTREXATE (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Methotrexate in the 10MM (US, France, Germany,

More information

Industry Analysis Competitor Analysis

Industry Analysis Competitor Analysis Course: Foundations of Business Strategy https://www.coursera.org/course/strategy101 To: Karl-Ludwig Kley, CEO - Merck KGaA From: Ju Yang Re: Merck KGaA Competitive Position Analysis in the Pharmaceuticals

More information

About The Report. Key Questions Answered in this Report:

About The Report. Key Questions Answered in this Report: About IMARC For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients

More information

COPD IN THE UK. Peter Barnes FRS, FMedSci National Heart & Lung Institute Imperial College London, UK

COPD IN THE UK. Peter Barnes FRS, FMedSci National Heart & Lung Institute Imperial College London, UK COPD IN THE UK Peter Barnes FRS, FMedSci National Heart & Lung Institute Imperial College London, UK MRC-ICMR Workshop on Chronic Diseases Delhi November 2009 Imperial College Royal Brompton Hospital Ischaemic

More information

Global Epilepsy Epidemiology and Patient Flow Analysis

Global Epilepsy Epidemiology and Patient Flow Analysis Brochure More information from http://www.researchandmarkets.com/reports/4030798/ Global Epilepsy Epidemiology and Patient Flow Analysis - 2017 Description: The results of the Epilepsy patients study are

More information

IMS Therapy Report: Asthma & COPD

IMS Therapy Report: Asthma & COPD Brochure More information from http://www.researchandmarkets.com/reports/481004/ IMS Therapy Report: Asthma & COPD Description: This extensively researched report combines IMS s gold standard data with

More information

Pipeline: Respiratory, Inflammation & Autoimmunity (RIA) Inhaled therapeutic leadership; spearheading immunology biologics

Pipeline: Respiratory, Inflammation & Autoimmunity (RIA) Inhaled therapeutic leadership; spearheading immunology biologics Pipeline: Respiratory, Inflammation & Autoimmunity (RIA) Inhaled therapeutic leadership; spearheading immunology biologics Bing Yao, Head of MedImmune Respiratory, Inflammation & Autoimmunity imed Respiratory:

More information

The Lilly Global Health Innovation Campaign

The Lilly Global Health Innovation Campaign The Lilly Global Health Innovation Campaign An Overview Dr. Evan Lee Vice President, Global Health Programs Eli Lilly and Company October 2012 Lilly Corporate Responsibility Lilly is Advancing its CR Portfolio

More information

REFERENCE CODE GDHC493DFR PUBLICAT ION DATE DECEMBER 2014 HUMIRA (ADALIMUMAB) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC493DFR PUBLICAT ION DATE DECEMBER 2014 HUMIRA (ADALIMUMAB) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC493DFR PUBLICAT ION DATE DECEMBER 2014 HUMIRA (ADALIMUMAB) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Humira (adalimumab) in the 10MM (US,

More information

J.P. MORGAN HEALTHCARE CONFERENCE

J.P. MORGAN HEALTHCARE CONFERENCE J.P. MORGAN HEALTHCARE CONFERENCE Bill Chase, Executive Vice President, Finance and CFO January 14, 2015 Disclaimer and Forward Looking Statement This presentation and its contents are confidential and

More information

AstraZeneca Development Pipeline: NCEs and line extensions 28 July 2005

AstraZeneca Development Pipeline: NCEs and line extensions 28 July 2005 AstraZeneca Development Pipeline: NCEs and line extensions 28 July 2005 Cardiovascular Exanta thrombin inhibitor prevention of VTE III Launched Filed* Exanta thrombin inhibitor (s.c) prevention of VTE

More information

Lilly Global External R&D find. fund. develop. Novel and Fully Integrated Approaches to Partnering with Eli Lilly

Lilly Global External R&D find. fund. develop. Novel and Fully Integrated Approaches to Partnering with Eli Lilly Lilly Global External R&D find. fund. develop. Novel and Fully Integrated Approaches to Partnering with Eli Lilly Dr. Jenny Laird Vice-President & Regional Head Global External R&D Europe-Australia- Canada

More information

Insulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020

Insulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020 Brochure More information from http://www.researchandmarkets.com/reports/2075322/ Insulin Degludec (Type 2 Diabetes) - Analysis and Forecasts to 2020 Description: Insulin Degludec (Type 2 Diabetes) Analysis

More information

Biosimilar Medicines for Rheumatologists: Understanding the Science of Extrapolation

Biosimilar Medicines for Rheumatologists: Understanding the Science of Extrapolation A Satellite Symposium at EULAR 2016 London, UK Organised by the BIOSIMILAR MEDICINES GROUP biosimilar medicines better access. better health. Biosimilar Medicines for Rheumatologists: Understanding the

More information

HEALTHCARE AND PHARMACEUTICAL MULTI-CLIENT STUDIES

HEALTHCARE AND PHARMACEUTICAL MULTI-CLIENT STUDIES HEALTHCARE AND PHARMACEUTICAL MULTI-CLIENT STUDIES IHS Global Insight s Multi-Client Studies (MCS) are designed to provide unique and in-depth insight to key questions and challenges facing the healthcare

More information

REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) GSK1572932A (NON-SMALL CELL LUNG CANCER) - Executive Summary GSK1572932A (MAGE-A3): Key Metrics in NSCLC Markets

More information

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact

Winter 2013. Changing landscapes, pipeline products and plan sponsor impact Winter 2013 Changing landscapes, pipeline products and plan sponsor impact Changing landscapes, pipeline products and plan sponsor impact The pharmaceutical landscape is changing as is the profile of blockbuster

More information

Patient Adherence Innovation through Personalization

Patient Adherence Innovation through Personalization Patient Adherence Innovation through Personalization Suzanne Wilmot Director, Novartis Patient Adherence The opinions expressed in this presentation and on the following slides are solely those of the

More information

UK Patients with Chronic Conditions Believe the Ability to Access Electronic Medical Records Outweighs Concern of Privacy Invasion

UK Patients with Chronic Conditions Believe the Ability to Access Electronic Medical Records Outweighs Concern of Privacy Invasion Insight Driven Health UK Patients with Chronic Conditions Believe the Ability to Access Electronic Medical Records Outweighs Concern of Privacy Invasion Accenture s research shows patients with chronic

More information

Sponsor Novartis Pharmaceuticals

Sponsor Novartis Pharmaceuticals Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study

More information

Methods for Measuring Dose Escalation in TNF Antagonists for Rheumatoid Arthritis Patients Treated in Routine Clinical Practice

Methods for Measuring Dose Escalation in TNF Antagonists for Rheumatoid Arthritis Patients Treated in Routine Clinical Practice Methods for Measuring Dose Escalation in TNF Antagonists for Rheumatoid Arthritis Patients Treated in Routine Clinical Practice Gu NY 1, Huang XY 2, Globe D 2, Fox KM 3 1 University of Southern California,

More information

Cardiovascular disease (CVD) is the leading cause of death in women, accounting for 54% of deaths in women in Europe

Cardiovascular disease (CVD) is the leading cause of death in women, accounting for 54% of deaths in women in Europe Red Alert for Women s Hearts Summary FACTS ON WOMEN AND CARDIOVASCULAR RESEARCH Cardiovascular disease (CVD) is the leading cause of death in women, accounting for 54% of deaths in women in Europe Women

More information

REFERENCE CODE GDHC495DFR PUBLICATION DATE DECEM BER 2014 SIMPONI (GOLIMUMAB) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC495DFR PUBLICATION DATE DECEM BER 2014 SIMPONI (GOLIMUMAB) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC495DFR PUBLICATION DATE DECEM BER 2014 SIMPONI (GOLIMUMAB) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Simponi (golimumab) in the 10MM (US,

More information

Home Healthcare Solutions. Brent Shafer, CEO Healthcare Home Healthcare Solutions

Home Healthcare Solutions. Brent Shafer, CEO Healthcare Home Healthcare Solutions 1 Home Healthcare Solutions Brent Shafer, CEO Healthcare Home Healthcare Solutions Home Healthcare Solutions focus Accelerating growth in: Sleep Respiratory Care Home Monitoring International expansion

More information

REFERENCE CODE GDHC520DFR PUBLICAT ION DATE DECEMBER 2014 IRRIBOW (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC520DFR PUBLICAT ION DATE DECEMBER 2014 IRRIBOW (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC520DFR PUBLICAT ION DATE DECEMBER 2014 IRRIBOW (IRRITABLE BOWEL SYNDROME) Executive Summary The Table below presents the key metrics of Astellas Irribow for Irritable Bowel Syndrome

More information

Autoimmune Diseases More common than you think Randall Stevens, MD

Autoimmune Diseases More common than you think Randall Stevens, MD Autoimmune Diseases More common than you think Randall Stevens, MD picture placeholder Autoimmune Diseases More than 60 different disorders Autoimmune disorders (AID) diseases caused by the immune system

More information

Developing a National Audit for Rheumatoid and Early Inflammatory Arthritis Ian Rowe

Developing a National Audit for Rheumatoid and Early Inflammatory Arthritis Ian Rowe Developing a National Audit for Rheumatoid and Early Inflammatory Arthritis Ian Rowe Chair Clinical Affairs Committee, BSR Outline The British Society for Rheumatology Challenges in improving patient outcomes

More information

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

More information

REFERENCE CODE GDHCER083-15 PUBLICAT ION DATE JULY 2015 MULTIPLE MYELOMA EPIDEMIOLOGY FORECAST TO 2023

REFERENCE CODE GDHCER083-15 PUBLICAT ION DATE JULY 2015 MULTIPLE MYELOMA EPIDEMIOLOGY FORECAST TO 2023 REFERENCE CODE GDHCER083-15 PUBLICAT ION DATE JULY 2015 MULTIPLE MYELOMA Executive Summary Multiple myeloma (MM) (International Statistical Classification of Diseases and Related Health Problems, 10th

More information

REFERENCE CODE GDHC346DFR PUBLICAT ION DATE FEBRUARY 2014 HUMIRA (ULCERATIVE COLITIS) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC346DFR PUBLICAT ION DATE FEBRUARY 2014 HUMIRA (ULCERATIVE COLITIS) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC346DFR PUBLICAT ION DATE FEBRUARY 2014 HUMIRA (ULCERATIVE COLITIS) - Executive Summary Table below provides a summary of the key metrics for Humira in the 10MM Ulcerative Colitis (UC)

More information

CAN-FITE BIOPHARMA LTD.

CAN-FITE BIOPHARMA LTD. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month

More information

Healthcare Spending Among Privately Insured Individuals Under Age 65

Healthcare Spending Among Privately Insured Individuals Under Age 65 Healthcare Spending Among Privately Insured Individuals Under Age 65 February 2012 Healthcare Spending Among Privately Insured Individuals Under Age 65 February 2012 Introduction Healthcare spending and

More information

Comprehensive Study on Availability of Epidemiology Data at a Granular Level for Bladder Cancer In Emerging Countries

Comprehensive Study on Availability of Epidemiology Data at a Granular Level for Bladder Cancer In Emerging Countries WHITE PAPER SMART DECISION SERVICES Comprehensive Study on Availability of Epidemiology Data at a Granular Level for Bladder Cancer In Emerging Countries Epidemiological investigation has become an essential

More information

REFERENCE CODE GDHC033POA PUBLICAT ION DATE J ANUARY 2014 DIABETIC FOOT ULCERS - OPPORTUNITY ANALYSIS AND FORECASTS TO EVENT-DRIVEN UPDATE

REFERENCE CODE GDHC033POA PUBLICAT ION DATE J ANUARY 2014 DIABETIC FOOT ULCERS - OPPORTUNITY ANALYSIS AND FORECASTS TO EVENT-DRIVEN UPDATE REFERENCE CODE GDHC033POA PUBLICAT ION DATE J ANUARY 2014 DIABETIC FOOT ULCERS - Executive Summary Below mentioned table presents the key metrics for diabetic foot ulcers (DFUs) in the six major pharmaceutical

More information

REFERENCE CODE GDHC206DFR PUBLICAT ION DATE JUNE 2013 NINTEDANIB (NON-SMALL CELL LUNG CANCER) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC206DFR PUBLICAT ION DATE JUNE 2013 NINTEDANIB (NON-SMALL CELL LUNG CANCER) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC206DFR PUBLICAT ION DATE JUNE 2013 NINTEDANIB (NON-SMALL CELL LUNG CANCER) - NINTEDANIB (NON-SMALL CELL LUNG CANCER) - Executive Summary Nintedanib: Key Metrics in NSCLC Markets 2022

More information

Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023

Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023 Brochure More information from http://www.researchandmarkets.com/reports/2989104/ Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023 Description: Bosatria (Mepolizumab) (Asthma) - Forecast

More information

TRANSFORMING BIG DATA INTO A HOLISTIC VIEW OF THE PATIENT INTEGRATED EHR, EMR, CHART AUDIT AND CLAIMS DATA SOLUTIONS

TRANSFORMING BIG DATA INTO A HOLISTIC VIEW OF THE PATIENT INTEGRATED EHR, EMR, CHART AUDIT AND CLAIMS DATA SOLUTIONS CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES TRANSFORMING BIG DATA INTO A HOLISTIC VIEW OF THE PATIENT INTEGRATED EHR, EMR, CHART AUDIT AND CLAIMS DATA SOLUTIONS WORLD-CLASS CLINICAL DATASETS

More information

The environment today - the opportunities & challenges of tomorrow

The environment today - the opportunities & challenges of tomorrow 09/03/2016 The environment today - the opportunities & challenges of tomorrow Alan Sheppard, Principal, Thought Leadership IMS Health 0 Brussels March 8/9 th 2016 Agenda Market growth, geographic and therapeutic

More information

Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022

Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and

More information

NHS outcomes framework and CCG outcomes indicators: Data availability table

NHS outcomes framework and CCG outcomes indicators: Data availability table NHS outcomes framework and CCG outcomes indicators: Data availability table December 2012 NHS OF objectives Preventing people from dying prematurely DOMAIN 1: preventing people from dying prematurely Potential

More information

About the ATLAS ACS Clinical Trial Program

About the ATLAS ACS Clinical Trial Program About the ATLAS ACS Clinical Trial Program Fast facts The ATLAS ACS clinical trials are global Phase II and Phase III studies evaluating the safety and efficacy of the anticoagulant rivaroxaban combined

More information

Building Bridges to Long-Term Growth

Building Bridges to Long-Term Growth N o 7 Building Bridges to Long-Term Growth Tanabe is working to realize its corporate philosophy of contributing to people over the world desiring to live healthy and securely through pharmaceuticals and

More information

REFERENCE CODE GDHC77PIDR PUBLICATION DATE JANUARY 2014 CROHN S DISEASE GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC77PIDR PUBLICATION DATE JANUARY 2014 CROHN S DISEASE GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC77PIDR PUBLICATION DATE JANUARY 2014 CROHN S DISEASE GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Crohn s Disease: Key Metrics in the Seven Major Pharmaceutical

More information

PUTTING THE FOCUS ON PSORIASIS AND PSORIATIC ARTHRITIS UNDERSTANDING THE IMPACT OF COMPLEX CHRONIC DISEASES BEYOND DIABETES AND HYPERTENSION

PUTTING THE FOCUS ON PSORIASIS AND PSORIATIC ARTHRITIS UNDERSTANDING THE IMPACT OF COMPLEX CHRONIC DISEASES BEYOND DIABETES AND HYPERTENSION PUTTING THE FOCUS ON AND PSORIATIC ARTHRITIS UNDERSTANDING THE IMPACT OF COMPLEX CHRONIC DISEASES BEYOND DIABETES AND HYPERTENSION WHAT IS? IS A CHRONIC INFLAMMATORY DISEASE THAT AFFECTS THE SKIN AND OTHER

More information

An Understanding of Biologics & Biosimilars

An Understanding of Biologics & Biosimilars An Understanding of Biologics & Biosimilars Emily Alexander Director, Regional Lead, U.S. Regulatory Affairs, AbbVie Hayden Rhudy Director, Therapeutic Area Strategies, AbbVie http://www.spinalcord.org/webinar-archive/

More information

Exploratory data: COPD and blood eosinophils. David Price: 9.23-9.35am

Exploratory data: COPD and blood eosinophils. David Price: 9.23-9.35am Exploratory data: COPD and blood eosinophils David Price: 9.23-9.35am Blood Eosinophilia in COPD The reliability and utility of blood eosinophils as a marker of disease burden, healthcare resource utilisation

More information

Global Multiple Sclerosis Epidemiology and Patient Flow Analysis - 2015

Global Multiple Sclerosis Epidemiology and Patient Flow Analysis - 2015 Brochure More information from http://www.researchandmarkets.com/reports/3070277/ Global Multiple Sclerosis Epidemiology and Patient Flow Analysis - 2015 Description: The author announced the results of

More information

2011 CMR INTERNATIONAL PHARMACEUTICAL R&D FACTBOOK

2011 CMR INTERNATIONAL PHARMACEUTICAL R&D FACTBOOK 2011 CMR INTERNATIONAL PHARMACEUTICAL R&D FACTBOOK JUNE 2011 CMR OVERVIEW CMR International, a Thomson Reuters business, is the world leader in global pharmaceutical R&D performance measurement. For close

More information

Global Multiple Myeloma Epidemiology and Patient Flow Analysis - 2015

Global Multiple Myeloma Epidemiology and Patient Flow Analysis - 2015 Brochure More information from http://www.researchandmarkets.com/reports/3070278/ Global Multiple Myeloma Epidemiology and Patient Flow Analysis - 2015 Description: The author announced the results of

More information

MERCÈ ROVIRA. How the European Institute for women s health supports health issues at an EU level

MERCÈ ROVIRA. How the European Institute for women s health supports health issues at an EU level MERCÈ ROVIRA How the European Institute for women s health supports health issues at an EU level Supporting women s health issues at the EU-level M. Mercè Rovira Regàs Board Member European Institute of

More information

ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH AWARDED TO JOHN JOSEPH VALENTINE MCMURRAY AND SALIM YUSUF

ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH AWARDED TO JOHN JOSEPH VALENTINE MCMURRAY AND SALIM YUSUF ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH AWARDED TO JOHN JOSEPH VALENTINE MCMURRAY AND SALIM YUSUF The Prize was awarded to the two scientists for their contribution in researching

More information

FastTest. You ve read the book... ... now test yourself

FastTest. You ve read the book... ... now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections

More information

Global Haemophilia Epidemiology and Patient Flow Analysis - 2015

Global Haemophilia Epidemiology and Patient Flow Analysis - 2015 Brochure More information from http://www.researchandmarkets.com/reports/3070298/ Global Haemophilia Epidemiology and Patient Flow Analysis - 2015 Description: The author announced the results of its Haemophilia

More information

Finding the Best Clinical Trial Investigators

Finding the Best Clinical Trial Investigators Finding the Best Clinical Trial Investigators Bill Gwinn, Vice-President Clinical Informatics Solutions February 7, 2012 SCOPE Summit for Clinical Operations Executives Global Site Selection, Feasibility

More information

Global Inflammatory Bowel Disease Market

Global Inflammatory Bowel Disease Market Brochure More information from http://www.researchandmarkets.com/reports/3175853/ Global Inflammatory Bowel Disease Market 2015-2019 Description: About Inflammatory Bowel Disease Inflammatory bowel disease

More information

Important Notice. Strategic Focus to Sustain Growth FY2016 Q2 October 28, Christophe Weber President & Chief Executive Officer

Important Notice. Strategic Focus to Sustain Growth FY2016 Q2 October 28, Christophe Weber President & Chief Executive Officer Strategic Focus to Sustain Growth FY2016 Q2 October 28, 2016 Christophe Weber President & Chief Executive Officer Important Notice Forward-Looking Statements This presentation contains forward-looking

More information

Results of Phase III Studies of Sitagliptin, new oral treatment of diabetes, were presented by Merck & Co., Inc. at ADA

Results of Phase III Studies of Sitagliptin, new oral treatment of diabetes, were presented by Merck & Co., Inc. at ADA June 12, 2006 Ono Pharmaceutical Co., Ltd., Public Relations Tel: +81-6-6263-5670 Banyu Pharmaceutical Co., Ltd., Public Relations Tel: +81-3-6272-1001 Results of Phase III Studies of Sitagliptin, new

More information

GSK Medicine: Study Number: Title: Rationale: Study Period: Objectives Indication: Study Investigators/Centers: Research Methods Data Source:

GSK Medicine: Study Number: Title: Rationale: Study Period: Objectives Indication: Study Investigators/Centers: Research Methods Data Source: GSK Medicine: Study Number: 08257 Title: OCSIGEN study Longitudinal follow-up of a cohort of patients with asthma treated with inhaled corticosteroids in primary care Rationale: In the Post-Licensing File

More information

Building a Serialization Compliance Management System. Lewis Kontnik, Director Brand Protection Amgen Inc. (Oct. 2012)

Building a Serialization Compliance Management System. Lewis Kontnik, Director Brand Protection Amgen Inc. (Oct. 2012) Building a Serialization Compliance Management System Lewis Kontnik, Director Brand Protection Amgen Inc. (Oct. 2012) About Amgen Amgen discovers, develops, manufactures, and delivers innovative human

More information

The Burden of the Complicated Type 2 Diabetes Patient in China. White Paper

The Burden of the Complicated Type 2 Diabetes Patient in China. White Paper White Paper Catalysts driving successful decisions in life sciences. The Burden of the Complicated Type 2 Diabetes Patient in China by Marco DiBonaventura, Ph.D. Director, Health Economics and Outcomes

More information

Current Topics in the Development and Regulatory Approval of Cancer Therapies

Current Topics in the Development and Regulatory Approval of Cancer Therapies Current Topics in the Development and Regulatory Approval of Cancer Therapies Michelle Ponpipom Associate Director Worldwide Regulatory Affairs Merck & Co., Inc. Oncology Drug Development: Dynamic & Evolving

More information

REFERENCE CODE GDHCER032-14 PUBLICAT ION DATE AUGUST 2014 RENAL CELL CARCINOMA - EPIDEMIOLOGY FORECAST TO 2023

REFERENCE CODE GDHCER032-14 PUBLICAT ION DATE AUGUST 2014 RENAL CELL CARCINOMA - EPIDEMIOLOGY FORECAST TO 2023 REFERENCE CODE GDHCER032-14 PUBLICAT ION DATE AUGUST 2014 RENAL CELL CARCINOMA - Executive Summary Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted

More information

Big Data for Population Health and Personalised Medicine through EMR Linkages

Big Data for Population Health and Personalised Medicine through EMR Linkages Big Data for Population Health and Personalised Medicine through EMR Linkages Zheng-Ming CHEN Professor of Epidemiology Nuffield Dept. of Population Health, University of Oxford Big Data for Health Policy

More information

GLOBAL MARKETS FOR GENERIC DRUGS

GLOBAL MARKETS FOR GENERIC DRUGS GLOBAL MARKETS FOR GENERIC DRUGS PHM009H February 2017 Paul Evers Project Analyst ISBN: 1-62296-437-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within the

More information

Inhaled Corticosteroids and the Risks

Inhaled Corticosteroids and the Risks Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression Journal Club October 13, 2010 By Anya Litvak, Kik Keiko Greenberg, and Jonathan Chrispin Background Inhaled corticosteroids are commonly

More information

Persistence Market Research

Persistence Market Research Persistence Market Research Global Obesity Surgery Devices Market Will Reach $2,489.5 Million in 2020 - Persistence Market Research Persistence Market Research 1 Persistence Market Research Released New

More information

Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety

Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of

More information

Step 2 Use the Medical Decision-Making Table

Step 2 Use the Medical Decision-Making Table Step 2 Use the Medical Decision-Making Table In Step 1, we determined the patient location and patient type. For most patient encounters, this determines the first 4 digits of the 5-digit CPT code. Three

More information

Philips Healthcare overview. Deborah DiSanzo, CEO Philips Healthcare

Philips Healthcare overview. Deborah DiSanzo, CEO Philips Healthcare Philips Healthcare overview Deborah DiSanzo, CEO Philips Healthcare Our focus Accelerate profitable growth Create value through solutions, clinical and business innovations Improve operational excellence

More information

Capital Markets Day, NYC 29 November 2012 T U R N I N G P E P T I D E S I N T O D R U G S

Capital Markets Day, NYC 29 November 2012 T U R N I N G P E P T I D E S I N T O D R U G S Lixisenatide (Lyxumia ): A novel once-daily GLP-1 agonist and lead Zealand drug invention, partnered with Sanofi in Type 2 diabetes by/ David Solomon, President and CEO Capital Markets Day, NYC 29 November

More information

Pattern of use of incretin-based medicines in a large sample of the Italian general population

Pattern of use of incretin-based medicines in a large sample of the Italian general population Pattern of use of incretin-based medicines in a large sample of the Italian general population Giuseppe Roberto, PharmD, PhD Regional Agency for Helathcare Services of Tuscany 7th European Congress of

More information

6.5 Cancer. 6. Priority diseases and reasons for inclusion. Background. See Background Paper 6.5 (BP6_5cancer.pdf)

6.5 Cancer. 6. Priority diseases and reasons for inclusion. Background. See Background Paper 6.5 (BP6_5cancer.pdf) 6.5 Cancer See Background Paper 6.5 (BP6_5cancer.pdf) Background Cancer (a term that includes over 100 types of malignancy) is one of the major burdens of chronic disease in Europe and the world (see Chapter

More information

Antares Pharma, Inc. Princeton South Corporate Center 100 Princeton South, Suite 300 Ewing, NJ 08628 NASDAQ : ATRS. Paul

Antares Pharma, Inc. Princeton South Corporate Center 100 Princeton South, Suite 300 Ewing, NJ 08628 NASDAQ : ATRS. Paul Antares Pharma, Inc. Princeton South Corporate Center 100 Princeton South, Suite 300 Ewing, NJ 08628 NASDAQ : ATRS Paul Antares Mission: To develop and commercialize self-administered parenteral medicines

More information

Cardiovascular Outcomes With Alogliptin in Patients With Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes

Cardiovascular Outcomes With Alogliptin in Patients With Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes Cardiovascular Outcomes With Alogliptin in Patients With Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes William B. White, MD for the EXAMINE Investigators Cardiology Center, University of

More information

Creating the World s Premier Biopharmaceutical Company. January 26, 2009

Creating the World s Premier Biopharmaceutical Company. January 26, 2009 Creating the World s Premier Biopharmaceutical Company January 26, 2009 Forward-Looking Statements and Non-GAAP Financial Information Discussions during this conference call will include forward-looking

More information

Development Pipeline as at 30 June 2013

Development Pipeline as at 30 June 2013 Line Extensions Cardiovascular Axanum*** Brilinta/ Brilique EUCLID Brilinta / Brilique PEGASUS- TIMI 54 Bydureon EXSCEL # Bydureon Dual Chamber Pen # (dapagliflozin)/ metformin FDC # (dapagliflozin) DECLARE

More information

4. Does your PCT provide structured education programmes for people with type 2 diabetes?

4. Does your PCT provide structured education programmes for people with type 2 diabetes? PCT Prescribing Report Drugs used in Type 2 Diabetes Discussion Points 1. Does your PCT have a strategy for prevention of type 2 diabetes? Does your PCT provide the sort of intensive multifactorial lifestyle

More information

THE VIRAL HEPATITIS CONGRESS 2015. 10 12 September 2015, Kap Europa, Frankfurt, Germany THE VIRAL HEPATITIS CONGRESS. Scientific Programme

THE VIRAL HEPATITIS CONGRESS 2015. 10 12 September 2015, Kap Europa, Frankfurt, Germany THE VIRAL HEPATITIS CONGRESS. Scientific Programme THE VIRAL HEPATITIS CONGRESS THE VIRAL HEPATITIS CONGRESS 2015 10 12 September 2015, Kap Europa, Frankfurt, Germany Scientific Programme PRE-CONGRESS WORKSHOP SPONSOR ACHILLION Achillion is seeking to

More information

New Prasugrel Head-to-Head Phase III Study Against Clopidogrel

New Prasugrel Head-to-Head Phase III Study Against Clopidogrel For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)

More information

REFERENCE CODE GDHC197DFR PUBLICAT ION DATE JUNE 2013 IRESSA (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC197DFR PUBLICAT ION DATE JUNE 2013 IRESSA (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC197DFR PUBLICAT ION DATE JUNE 2013 IRESSA (NON-SMALL CELL LUNG CANCER) Executive Summary Iressa (gefitinib): Key Metrics in NSCLC Markets 2012 Iressa Sales US 5EU Japan China India Total

More information

European Commission Approves EFIENT (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI

European Commission Approves EFIENT (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)

More information

Electronic Medical Record Access Outweighs Privacy Concerns for Chronic Patients in Norway

Electronic Medical Record Access Outweighs Privacy Concerns for Chronic Patients in Norway Insight Driven Health Electronic Medical Record Access Outweighs Privacy Concerns for Chronic Patients in Norway Accenture research shows persons with chronic conditions in Norway are more concerned about

More information

Exane Healthcare Conference

Exane Healthcare Conference Exane Healthcare Conference Jérôme Contamine, Executive Vice President, Chief Financial Officer Paris, March 18, 2015 Forward Looking Statements This presentation contains forward-looking statements as

More information

Growth in revenue from MS drugs has been driven largely by price increases over the last several years.

Growth in revenue from MS drugs has been driven largely by price increases over the last several years. March 4, 2013 Ben Weintraub, PhD Are Injectable MS Drugs Finished? Market Ready for Tecfidera Companies: Biogen (BIIB) Sanofi (SNY) Teva (TEVA) Novartis (NVS) Merck Serono Bayer Schering Products: Tecfidera

More information

The Japan Generic Market Drivers and Obstacles for Change. Matt Heimerdinger Anterio Inc.

The Japan Generic Market Drivers and Obstacles for Change. Matt Heimerdinger Anterio Inc. The Japan Generic Market Drivers and Obstacles for Change Matt Heimerdinger Anterio Inc. Quick country overview Osaka Tokyo Population: 127,520,000 Life expectancy: Male: 79.9; Female: 86.4 Pharmaceutical

More information

Hovione Product Development & Licensing

Hovione Product Development & Licensing Hovione Product Development & Licensing Courtney R Smith Bio Europe Conference: Delivery Track Wednesday, November 5, 2014 Agenda Hovione overview Product Development & Licensing Integrated approach to

More information

Biologic Treatments for Rheumatoid Arthritis

Biologic Treatments for Rheumatoid Arthritis Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been

More information

Announcing the results of China s COPD market research report

Announcing the results of China s COPD market research report September 9, 2016 Social Survey Research Information Co., Ltd. Announcing the results of China s COPD market research report - Increasing number of patients, with physicians citing air pollution as the

More information

The Top 10 Generic Pharmaceutical Companies

The Top 10 Generic Pharmaceutical Companies BUSINESS INSIGHTS The Top 10 Generic Pharmaceutical Companies Positioning, performance and SWOT analyses Market position of the global top 10 generics companies Among the global top 10 generic players,

More information

In the next decade need and demand will increase by at least 20 % so what can we do?

In the next decade need and demand will increase by at least 20 % so what can we do? In the next decade need and demand will increase by at least 20 % so what can we do? We have had 2 healthcare revolutions, with amazing impact The First was the public health revolution The Second has

More information